Arcutis Biotherapeutics (ARQT) Price & Analysis

Compare

865 Followers

ARQT Stock Chart & Stats

Day’s Range― - ―

52-Week Range$8.03 - $17.75

Previous CloseN/A

Volume446.87K

Average Volume (3M)1.54M

Market Cap

$1.83B

Enterprise Value$1.88B

Total Cash (Recent Filing)$198.09M

Total Debt (Recent Filing)$110.80M

Price to Earnings (P/E)―

Beta1.39

Next Earnings

Nov 05, 2025

EPS Estimate

-0.09

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.13

Shares Outstanding119,201,720

10 Day Avg. Volume1,409,149

30 Day Avg. Volume1,539,589

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market Cap1.03

Enterprise Value/Revenue8.85

Enterprise Value/Gross Profit10.01

Enterprise Value/Ebitda-18.63

Forecast

1Y Price Target

$21.41

Price Target Upside39.75% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering8

Bulls Say, Bears Say

Bulls Say

Label ExpansionZoryve’s label expansion in plaque psoriasis is expected to drive sustained revenue growth.

Product AdvantagesZoryve cream and foam offer one treatment for all body parts from head to toe for long periods of time—a unique advantage that patients and dermatologists would welcome.

Bears Say

Market CompetitionCommercial success is not assured since dermatology remains a highly competitive segment of the market.

Product Concentration RiskZoryve is the company's only commercial asset, presenting a product concentration risk.

Arcutis Biotherapeutics News

Arcutis Biotherapeutics price target raised to $25 from $20 at TD Cowen

TD Cowen raised the firm’s price target on Arcutis Biotherapeutics (ARQT) to $25 from $20 and keeps a...

11h ago

ARQT

Arcutis Biotherapeutics price target raised to $22 from $19 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Arcutis Biotherapeutics (ARQT) to $22 from $19 and keeps a...

15h ago

ARQT

Arcutis Biotherapeutics reports Q2 EPS (13c), consensus (16c)

Reports Q2 revenue $81.5M, consensus $73.67M. “We continue to advance our strategy to become the leading medical dermatology...

1d ago

ARQT

Carvana upgraded, Ulta Beauty downgraded: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here...

13d ago

Arcutis Biotherapeutics initiated with a Neutral at Goldman Sachs

Goldman Sachs initiated coverage of Arcutis Biotherapeutics (ARQT) with a Neutral rating and $18 price target The company’s...

14d ago

ARQT

Arcutis Biotherapeutics: Promising Growth Driven by Zoryve’s Success and Strategic Initiatives

Analyst Douglas Tsao of H.C. Wainwright reiterated a Buy rating on Arcutis Biotherapeutics, boosting the price target to...

14h ago

ARQT

Arcutis Biotherapeutics Reports Strong Q2 2025 Growth

Arcutis Biotherapeutics Inc ( ($ARQT) ) has released its Q2 earnings. Here is a breakdown of the information...

20h ago

ARQT

Arcutis Biotherapeutics: Strong Performance and Growth Potential Drive Buy Rating

Analyst Tyler Van Buren from TD Cowen maintained a Buy rating on Arcutis Biotherapeutics and increased the price...

1d ago

ARQT

Arcutis Biotherapeutics Completes Promising Psoriasis Treatment Study

Arcutis Biotherapeutics Inc (($ARQT)) announced an update on their ongoing clinical study. Arcutis Biotherapeutics Inc. recently completed a...

21d ago

ARQT

Arcutis Biotherapeutics assumed with an Overweight at Morgan Stanley

Morgan Stanley assumed coverage of Arcutis Biotherapeutics (ARQT) with an Overweight rating and a price target of $20,...

1M ago

ARQT

Arcutis announces ZORYVE cream receives strong recommendation from AAD

Arcutis Biotherapeutics (ARQT) announced that ZORYVE cream 0.15% has received a strong recommendation in the focused guideline update...

1M ago

ARQT

Arcutis Biotherapeutics Approves Key Proposals at Annual Meeting

An announcement from Arcutis Biotherapeutics ( ($ARQT) ) is now available. On June 12, 2025, Arcutis Biotherapeutics held...

2M ago

ARQT

Arcutis Biotherapeutics enrolls first child in INTEGUMENT-INFANT

Arcutis Biotherapeutics (ARQT) announced that the first child has been enrolled in a Phase 2 open-label study, INTEGUMENT-INFANT,...

2M ago

ARQT

Arcutis Biotherapeutics presents new long-term results of ZORYVE cream

Arcutis Biotherapeutics (ARQT) announced that it will present five posters at the 2025 Revolutionizing Atopic Dermatitis, RAD, Conference,...

2M ago

ARQT

ARQT FAQ

What was Arcutis Biotherapeutics Inc’s price range in the past 12 months?

Arcutis Biotherapeutics Inc lowest stock price was $8.03 and its highest was $17.75 in the past 12 months.

What is Arcutis Biotherapeutics Inc’s market cap?

Arcutis Biotherapeutics Inc’s market cap is $1.83B.

When is Arcutis Biotherapeutics Inc’s upcoming earnings report date?

Arcutis Biotherapeutics Inc’s upcoming earnings report date is Nov 05, 2025 which is in 89 days.

How were Arcutis Biotherapeutics Inc’s earnings last quarter?

Arcutis Biotherapeutics Inc released its earnings results on Aug 06, 2025. The company reported -$0.13 earnings per share for the quarter, beating the consensus estimate of -$0.145 by $0.015.

Is Arcutis Biotherapeutics Inc overvalued?

According to Wall Street analysts Arcutis Biotherapeutics Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Arcutis Biotherapeutics Inc pay dividends?

Arcutis Biotherapeutics Inc does not currently pay dividends.

What is Arcutis Biotherapeutics Inc’s EPS estimate?

Arcutis Biotherapeutics Inc’s EPS estimate is -0.09.

How many shares outstanding does Arcutis Biotherapeutics Inc have?

Arcutis Biotherapeutics Inc has 119,201,720 shares outstanding.

What happened to Arcutis Biotherapeutics Inc’s price movement after its last earnings report?

Arcutis Biotherapeutics Inc reported an EPS of -$0.13 in its last earnings report, beating expectations of -$0.145. Following the earnings report the stock price went down -4.33%.

Which hedge fund is a major shareholder of Arcutis Biotherapeutics Inc?

Currently, no hedge funds are holding shares in ARQT

Arcutis Biotherapeutics Stock Smart Score

Outperform

Fundamentals

Return on Equity

-70.58%

Trailing 12-Months

Asset Growth

-28.09%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics, Inc. (ARQT) is a biopharmaceutical company dedicated to developing and commercializing innovative dermatological therapies. The company focuses on creating treatments for immune-mediated dermatological diseases and conditions. Arcutis's core products include topical creams and ointments designed to address conditions such as psoriasis and eczema, aiming to improve patient outcomes through advanced drug formulations.

Arcutis Biotherapeutics (ARQT) Earnings & Revenues

Historic Earnings Reports

ARQT Company Deck

ARQT Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call reflects a strong performance by Arcutis with significant revenue growth and positive developments in their pipeline and market expansion. However, there are challenges related to increased SG&A expenses and typical first-quarter revenue declines. The overall sentiment is bolstered by the strategic management of IP and positive prescription trends despite seasonal challenges.View all ARQT earnings summaries

ARQT Stock 12 Month Forecast

Average Price Target

$21.41

▲(39.75% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"7":"$7","30":"$30","12.75":"$12.75","18.5":"$18.5","24.25":"$24.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":29,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$29.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":21.41,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$21.41</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":14.29,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$14.29</span>\n  </div></div>","useHTML":true}}],"tickPositions":[7,12.75,18.5,24.25,30],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.75,14.923076923076923,16.096153846153847,17.26923076923077,18.442307692307693,19.615384615384617,20.78846153846154,21.96153846153846,23.134615384615387,24.307692307692307,25.480769230769234,26.653846153846153,27.826923076923077,{"y":29,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.75,14.339230769230769,14.928461538461539,15.517692307692307,16.106923076923078,16.696153846153848,17.285384615384615,17.874615384615385,18.463846153846156,19.053076923076922,19.642307692307693,20.231538461538463,20.82076923076923,{"y":21.41,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.75,13.791538461538462,13.833076923076923,13.874615384615385,13.916153846153845,13.957692307692307,13.999230769230769,14.04076923076923,14.082307692307692,14.123846153846154,14.165384615384614,14.206923076923076,14.248461538461537,{"y":14.29,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":9.56,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.48,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.88,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.55,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.67,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.42,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.93,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.24,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.69,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.98,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.65,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.48,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.75,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >